FIELMANN AG (ADR/1/5)O.N.

Fielmann shares rose sharply after a buy recommendation from Deutsche Bank; the chart suggests a completed base formation and possible substantial recovery. Operationally, the company remained below usual growth rates in Q1 with a slight revenue increase to €613m and stable adjusted EBITDA of €149m, which management attributed to extreme weather events. Fielmann confirmed its full-year guidance of 5–7% revenue growth and an adjusted EBITDA margin of 23% as well as its mid-term plan to nearly double revenue by 2030 with a 25% margin. The stock appears historically cheap with a KGV 2026 of around 16 and could be interesting for longer-term investors. » Więcej na finanzen.net

Fielmann forecasts a 5–7% increase in sales for 2026 to €2.55–2.6 billion and an adjusted Ebitda of about €590–610 million (margin roughly 23%). Investments in expansion and the rollout of AI‑assisted refraction technology, along with broader availability of eye tests in the US, should support growth but will weigh on margins in the short term. In the first quarter, sales rose 1.3% to €613 million, while adjusted Ebitda was almost unchanged at €149 million; extreme weather events temporarily hit business. » Więcej na finanzen.net

A buy recommendation from Bank of America is driving the Fielmann share, which at times rose by more than 6 percent and settled at a chart barrier around €45. BofA sees lower risks, highlights accelerated growth in the US and regards the share price level as historically low. The sales target of four billion euros for 2030 is not yet priced into market expectations; additionally, Fielmann benefits from low dependence on oil prices and low freight costs. » Więcej na de.investing.com